NOVEL RP-HPLC METHOD FOR THE QUANTIFICATION OF ABIRATERONE ACETATE

SG Vasantharaju

Abstract

Simple, rapid, accurate and specific RP-HPLC method has been developed for quantitative estimation of
Abiraterone acetate in bulk and tablet. Separation was attained by using Acclaim C18 column (50mm x
4.6 mm, 5) at 25C and 80:20 v/v acetonitrile:ammonium acetate buffer(10mM) of pH 6.0 with flow rate
of 1ml/min as mobile phase and the drug was detected at 254 nm. Analytical method was said to be
linear over a range of 0.125-60 g/ml with correlation constant of 0.999. Method was appeared to be
precise, robust and rugged. LOD and LOQ were found to be 10 ng/ml and 50 ng/ml respectively and the
mean recovery value as 100.52%.Stability indicating capability of this method has been demonstrated by
analyzing stressed samples of drug and found labile to acidic, alkaline, oxidative, thermal and photolytic
conditions. Above method was applied for the estimation in API, formulation and dissolution testing of
the dosage form. Percentage assay of the formulation was found to be 101.66%w/w. Drug released to an
extent of 85.29% at 30 minutes as per FDA published method. Thus, the analytical procedure is reliable
and offers advantage in terms of speed; so could be effectively used for the routine quality control
purpose.

Full Text:

PDF

References

Food and Drug Administration Approves

Abiraterone for Treatment of Men with

Advanced Prostate Cancer. Available

from:

http://www.pcf.org/site/c.leJRIROrEpH/b.

/k.82CC/

Food_and_Drug_Administration_Approve

s_Abiraterone_for_Treatment_of_Men_wit

h_Advanced_Prostate_Cancer.htm

Abiraterone Acetate (CAS 154229-18-2).

Available from:

http://www.scbt.com/datasheet-207240-

abiraterone-acetate.html

Oxidation stability of abiraterone acetate

WO 2014009437 A1. Available from:

http://www.google.com/patents/WO201400

A1?cl=en

Zytiga. Available from:

http://www.globalrph.com/drug_abiratero

ne.htm

Chemistry Review (S). Available from:

http://www.accessdata.fda.gov/drugsatfda

_docs/nda/2011/202379Orig1s000ChemR.

pdf

Martins V, Asad Y, Wilsher N, Raynaud

F, A validated liquid chromatographic–

tandem mass spectroscopy method for the

quantification of abiraterone acetate and

abiraterone in human plasma. J

Chromatogr B Analyt Technol Biomed

Life Sci. 2006;843(2):262-267.

Gaurav S, Punde R, Farooqui J,

Zainuddin M, Rajagopal S, Mullangi R,

Development and validation of a highly

sensitive method for the determination of

abiraterone in rat and human plasma by

LC-MS/MS-ESI: application to a

pharmacokinetic study. Biomed

Chromatogr. 2012;26(2):761-8.

Kumar SV, Rudresha G, Gaurav S,

Zainuddin,Dewang P, Kethiri RR,

Rajagopal S, Mullangi R, Validated RPHPLC/

UV method for the quantitation of

abiraterone in rat plasma and its

application to a pharmacokinetic study in

rats. Biomed Chromatogr. 2013; 27(2):

-7.

Khdera A, Darwish I, Bamanea F,

Analysis of abiraterone stress degradation

behavior using liquid chromatography

coupled to ultraviolet detection and

electrospray ionization mass

spectrometry. J Pharm Biomed

Anal. 2013; 23:74-77.

Gong A, Zhu X, β-cyclodextrin Sensitized

Spectrofluorimetry for the Determination

of Abiraterone Acetate and

Abiraterone. J.

Fluoresc. 2013;23(6):1279-86.

International Conference on

Harmonization, Note for guidance on

stability testing of new drug substance

and products [ICH, Q1A (R2)]. In:

International conference on

harmonization of technical requirement

for registration of pharmaceutical for

human use, Geneva (2003).

International Conference on

Harmonization, Note for guidance on

Impurities in New Drug Products [ICH,

Q3B (R2)]. In: International conference

on harmonization of technical

requirement for registration of

pharmaceutical for human use, Geneva

(2006).

International Conference on

Harmonization, Note for guidance on

Validation of Analytical Procedures: Test

and Methodology [ICH, Q2 (R1)]. In:

International conference on

harmonization of technical requirement

for registration of pharmaceutical for

human use, Geneva, 2005. Available

form:http://www.ich.org/fileadmin/Public

_Web_Site/ICH_Products/Guidelines/Qua

lity/Q2_R1/Step4/Q2_R1__Guideline.pdf

Office of Generic Drugs,

FDA. Dissolution method for abiraterone

acetate. Available

from:http://www.accessdata.fda.gov/scrip

ts/cder/dissolution/dsp_SearchResults_Di

ssolutions.cfm

USP Pending Monograph-Abiraterone

acetate. Available from:

http://www.usp.org/sites/default/files/usp

_pdf/EN/USPNF/m7730.pdf

Refbacks

  • There are currently no refbacks.